March 26, 2026

AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?

The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New E...

The ASCO Post

March 24, 2026

Will Circulating Tumor DNA Help Predict HPV-Related Throat Cancer?

A Keck Medicine of USC head and neck surgeon discusses circulating HPV DNA as a biomarker that could help make more individualized treatment decisions.

Keck Medicine of USC

March 24, 2026

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or re...

The ASCO Post

March 24, 2026

POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings

POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monocl...

The ASCO Post

March 24, 2026

Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could...

The ASCO Post

March 24, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

The ASCO Post

March 24, 2026

A Decade of Research Leads to New Guidance on Using Colony-Stimulating Factors in Anticancer Treatment

ASCO has published an updated guideline describing the latest evidence on using hematopoietic colony-stimulating factor (CSF) to support anticancer treatment, namely chemotherapy and stem cell transpl...

The ASCO Post

March 24, 2026

New First-Line Targeted Therapy Recommendations Among Updated ASCO Guidance on Gastroesophageal Cancer Management

ASCO has released a guideline update addressing advances in the use of immunotherapy and targeted therapy for the treatment of advanced gastroesophageal cancer.1 The guideline, last updated in 2023 to...

The ASCO Post

March 24, 2026

No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma

Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response af...

The ASCO Post

March 24, 2026

Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer

Biomarker discovery in colorectal cancer has traditionally focused on identifying molecular alterations with broad prognostic or predictive utility. However, evidence is increasingly suggesting that b...

The ASCO Post